Lunai Bioworks Inc.

Stage 4 · Declining · week 10

As of Oct 22, 2026, Lunai Bioworks is in Stage 4, the downtrend phase, now in week 10 (since Aug 13, 2026). It closed at $0.47, 96.1% below its 52-week high and below its 200-day average, which is falling.

Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States, Canada, and the Netherlands. More about the company

$0.47

-6.00% today

$2.1M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is LNAI early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 33w

S4 70w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 1w → S1 2w → S2 13w → S3 6w → S2 6w → S3 7w → S4 33w → S1 8w → S2 3w → S3 1w → S4 70w → S1 6w → S4 10w current

Total tracked: 165 weeks across 13 stage runs.

LNAI among Biotechnology528th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…528	LNAILunai Bioworks Inc.	Stage 4 · wk 10	5	−78.0%

vs 52W High

-96.1%

$0.47 lo$12.00 hi

96.1% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 10

1w13w26w

Week 10, established downtrend

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-84.8%

200 DMA: $3.09 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

2.00x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-78.0%

-79.8%

-80.7%

YTD

-94.0%

-95.4%

Scan Membership

Breakout Watch

Latest: 2025-02-03

8 appearances in last 60 days. First seen: 2018-11-20.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 10 · Vol 2.00x

2026-10-21S4

Wk 10 · Vol 1.28x

2026-10-20S4

Wk 10 · Vol 3.26x

2026-10-19S4

Wk 10 · Vol 3.20x

2026-10-16S4

Wk 10 · Vol 1.27x

2026-10-15S4

Wk 9 · Vol 0.59x

2026-10-14S4

Wk 9 · Vol 0.87x

2026-10-13S4

Wk 9 · Vol 0.19x

2026-10-12S4

Wk 9 · Vol 0.41x

2026-10-09S4

Wk 9 · Vol 3.83x

2026-10-08S4

Wk 8 · Vol 0.07x

2026-10-07S4

Wk 8 · Vol 0.09x

Moving averages & range

50 DMA

$1.80

200 DMA

$3.09

52W High

$12.00

52W Low

$0.47

5D Low

$0.47

Resistance levels (recent highs)

20d High

$1.93

60d High

$2.61

120d High

$4.30

250d High

$12.00

Next resistance

+310.6%

to 20d High

Dividend Yield

0.00%

P/B -0.2

Lunai Bioworks: quick answers

What stage is Lunai Bioworks in?

As of Oct 22, 2026, Lunai Bioworks (LNAI) is in Stage 4, the downtrend phase. It entered Stage 4 on Aug 13, 2026 and is in week 10. What the four stages mean

Is Lunai Bioworks in an uptrend?

No. Lunai Bioworks is in a Stage 4 downtrend. It trades 84.8% below its 200-day average, which is falling.

How far is Lunai Bioworks from its 52-week high?

Lunai Bioworks closed at $0.47 on Oct 22, 2026, 96.1% below its 52-week high of $12.00. Its 52-week low is $0.47.

How has Lunai Bioworks performed over the past year?

As of Oct 22, 2026, Lunai Bioworks is down 95.4% over the past year and down 94.0% so far in 2026.

Which sector and industry is Lunai Bioworks in?

Lunai Bioworks is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States, Canada, and the Netherlands. It operates through two segments, RENB and BioSymetrics. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer. It also develops BioSymetrics platform, for multi-omics integration for target identification and validation; clinical trial optimization, including patient stratification and response monitoring; and screening of gene and small molecule effects for the purpose of identifying novel drug targets and therapeutics. The company was formerly known as Renovaro Inc. and changed its name to Lunai Bioworks Inc. in August 2025. Lunai Bioworks Inc. is based in Sacramento, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.